Articles: nausea.
-
Clinical therapeutics · Feb 2003
Randomized Controlled Trial Comparative Study Clinical TrialGranisetron versus granisetron/dexamethasone combination for the treatment of nausea, retching, and vomiting after major gynecologic surgery: a randomized, double-blind study.
Granisetron, a selective 5-hydroxytryptamine3 antagonist, is effective for the treatment of patients with postoperative nausea and vomiting. Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen. ⋯ In this study, the granisetron/dexamethasone combination was more effective than was granisetron alone for the management of nausea and vomiting during 0 to 3 hours after anesthesia in women undergoing major gynecologic surgery.
-
J Pediatr Ophthalmol Strabismus · Jan 2003
Randomized Controlled Trial Comparative Study Clinical TrialComparison of anti-emetic effects of ondansetron and low-dose droperidol in pediatric strabismus surgery.
Strabismus surgery is associated with a high incidence of postoperative nausea and vomiting. A dose of 150 microg/kg(-1) of ondansetron has been found to be effective in reducing nausea and vomiting in pediatric patients. However, droperidol (20 to 75 microg/kg(-1)) has shown variable success with various side effects. This randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy and safety of 25 microg/kg(-1) of droperidol and compare it with that of 150 microg/kg(-1) of ondansetron in pediatric strabismus surgery. ⋯ Doses of 25 microg/kg(-1) of droperidol and 150 microg/kg(-1) of ondansetron administered at induction of anesthesia are equally effective in reducing the incidence and severity of postoperative nausea and vomiting in children undergoing strabismus surgery.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Standard-dose (2 mg/day) oral granisetron seems to have more antiemetic efficacy than that of high-dose (0.5-1 mg/kg/dose) metoclopramide in moderately emetogenic chemotherapy. However, the cost of oral granisetron is much higher than that of metoclopramide so the authors tried to overcome this disadvantage by dose reduction and adding dexamethasone to enhance the antiemetic effect of oral granisetron. Twenty four young patients (aged < 50 years), with non-Hodgkin's lymphoma receiving CHOP-therapy were enrolled and evaluated in a randomized, double-blind, crossover study comparing the antiemetic efficacy, toxicity and patients' preference of a combination of low-dose oral granisetron plus intravenous dexamethasone (gran/dex) with a combination of high-dose metoclopramide plus intravenous dexamethasone (met/dex) on days 1-5 after chemotherapy. ⋯ The mean total score of antiemetic preference in the gran/dex group was also significantly higher than that of the met/dex group (9.0 vs 7.5; p-value = 0.004). In conclusion, low-dose oral granisetron combined with intravenous dexamethasone had significantly higher protective effects against both acute and delayed nausea and vomiting induced by CHOP-therapy. Thus, this regimen may be considered as an alternative outpatient antiemetic treatment for young patients with non-Hodgkin's lymphoma.
-
J Cataract Refract Surg · Nov 2002
Randomized Controlled Trial Comparative Study Clinical TrialNausea and vomiting after phacoemulsification using topical or retrobulbar anesthesia.
To determine and compare the incidence of postoperative nausea and vomiting in patients having phacoemulsification under topical or retrobulbar anesthesia. ⋯ Topical and retrobulbar anesthesia were associated with a low incidence of PONV in routine phacoemulsification. There were no statistically significant differences in PONV between the 2 anesthesia techniques. No significant correlation was found between the incidence of PONV and the duration of surgery, presence of complications, fasting time, postoperative IOP, or history of PONV or motion sickness.
-
Zhonghua Zhong Liu Za Zhi · Sep 2002
Randomized Controlled Trial Multicenter Study Clinical Trial[Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].
To evaluate the efficacy and safety of nausea oral, disintegrating buccal tablet (DBT) in the prevention of gastrointestinal reaction induced by anticancer drugs (cisplatin DDP 30 - 50 mg/m(2) or adramycin ADM >/= 40 mg/m(2)), as compared with those of kytril tablets. ⋯ Nausea disintegrating buccal tablet is able to effectively prevent gastrointestinal reaction induced by anticancer drugs, with efficacy and side effects similar to kytril tablets. Nausea DB tablet, an intraoral disintegrator, is very convenient for patients who can not swallow tablets for various reasons.